eligibility_summary
Eligible: adults 18–75 with relapsed/refractory NHL, CD19/CD20+, ≥1 measurable lesion, ECOG 0–2, life expectancy ≥3 months, adequate organ function, women of childbearing potential need negative pregnancy test and contraception, consent required. Exclude: significant cardiac disease, active GVHD, severe lung disease, other active malignancy, uncontrolled infection, severe autoimmunity/immunodeficiency, active hepatitis, HIV/AIDS/syphilis, severe biologic allergy, mental illness, pregnancy/lactation, or per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Double-target CART-19/20 autologous CAR T cells, with lymphodepleting cyclophosphamide and fludarabine. Mechanisms: Patient T cells are engineered to express CARs that bind CD19 and CD20 on B cells, dual antigen recognition is designed to limit antigen escape and trigger robust T-cell activation, proliferation, cytokine release, and cytotoxic killing, causing depletion of malignant (and normal) B cells. Cyclophosphamide (alkylating DNA crosslinker) and fludarabine (purine analog antimetabolite) provide lymphodepletion/immunosuppression to enhance CAR T expansion and persistence. Targets: CD19/CD20-expressing B-cell lymphomas and T-cell effector pathways.